L9169
L-838,417
≥98% (HPLC)
别名:
3-(2,5-Difluorophenyl)-7-(1,1-dimethylethyl)-6-[(1-methyl-1H-1,2,4-triazol-5-yl)methoxy]-1,2,4-triazolo[4,3-b]pyridazine
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C19H19F2N7O
化学文摘社编号:
分子量:
399.40
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
产品名称
L-838,417, ≥98% (HPLC)
InChI
1S/C19H19F2N7O/c1-19(2,3)13-8-15-24-25-17(12-7-11(20)5-6-14(12)21)28(15)26-18(13)29-9-16-22-10-23-27(16)4/h5-8,10H,9H2,1-4H3
SMILES string
Cn1ncnc1COc2nn3c(nnc3cc2C(C)(C)C)-c4cc(F)ccc4F
InChI key
BQDUNOMMYOKHEP-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
color
white to off-white
solubility
DMSO: ≥20 mg/mL
originator
Merck & Co., Inc., Kenilworth, NJ, U.S.
storage temp.
−20°C
Biochem/physiol Actions
L-838,417 is a novel pharmacology with no efficacy at a 1 subtype, but is partial agonist with equal efficacy at α2, K3 and α5 subtypes.
L-838,417 is a partial agonist with equal efficacy at α2, K3, and α5 subtypes.
Features and Benefits
This compound is featured on the GABAA Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
存储类别
13 - Non Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
法规信息
新产品
此项目有
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持